Business Context and Reporting Period
CytomX Therapeutics, Inc. (CTMX) filed a Form 8-K on February 24, 2025, regarding a notice received from the Nasdaq Stock Market. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on stock listing compliance.
Material Changes
The Company received a written notice from Nasdaq stating that its common stock failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days between January 8, 2025, and February 21, 2025. This constitutes a failure to satisfy Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has 180 calendar days, until August 25, 2025, to regain compliance. To do so, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days before the compliance date.
- Secondary Compliance Option: If the Company fails to regain compliance by August 25, 2025, it may be eligible for an additional 180-day period. This requires transferring its listing to the Nasdaq Capital Market and meeting all applicable initial listing standards for that market (except the minimum bid price requirement).
- Delisting Risk: If the Company cannot cure the deficiency or meet other listing standards, Nasdaq may issue a delisting notice. The Company may appeal such a determination to a Nasdaq Hearing Panel, though success is not assured.
- Management Action: Management intends to monitor the bid price and implement business strategies to increase value, though there is no assurance that compliance will be regained.
Investor Verification Checklist
- Verify the current trading price of CTMX common stock relative to the $1.00 minimum bid price requirement.
- Monitor the Company's stock performance over the next 180 days to assess the likelihood of meeting the ten-day consecutive trading threshold.
- Review future filings for any announcements regarding a potential transfer to the Nasdaq Capital Market.
- Check for any subsequent notices from Nasdaq regarding the Company's ability to cure the deficiency or potential delisting determinations.